Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Somatropin - Novo Nordisk

Drug Profile

Somatropin - Novo Nordisk

Alternative Names: NN-1610; NN-220; Norditropin; Norditropin cartridge; Norditropin FlexPro; Norditropin NordiFlex; Norditropin NordiLet; Norditropin NordiPen; Norditropin S; Norditropin SimpleXx; Somatotropin - Novo Nordisk

Latest Information Update: 09 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novo Nordisk
  • Class Growth hormones; Hormonal replacements; Obesity therapies
  • Mechanism of Action Somatotropin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Short stature; Female infertility; Somatotropin deficiency
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Dwarfism; Growth disorders; Short stature; Somatotropin deficiency
  • Discontinued Female infertility; Fracture; Nutrition disorders

Most Recent Events

  • 09 Jul 2019 Discontinued - Phase-III for Short stature (In children) in South Korea (SC) as no development reported after, December 2014 (NCT01778023)
  • 12 Jul 2018 Novo Nordisk completes a phase III trial in Short Stature (In children with Noonan Syndrome) in Japan (NCT01927861)
  • 01 Apr 2016 Final adverse events and efficacy data from a phase III trial in Idiopathic short stature presented at the The 98th Annual Meeting of the Endocrine Society (ENDO-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top